Gatipotuzumab Biosimilar - Research Grade

Human

MUC1

>1mg/ml

IgG1 - kappa

CHO Cells

Sontuzumab Biosimilar - Research Grade (ICH5876)

https://www.imgt.org/mAb-DB/

ICH3002

P15941

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of gatipotuzumab (also known as PankoMab-GEX), a humanized IgG1/kappa antibody directed against the tumor-associated glycoform of MUC1 (TA-MUC1). It is manufactured for research use only and is not the clinical drug; it is not intended for human or veterinary use. The analog reproduces the antigen-binding specificity of the originator, which recognizes a conformational epitope centered on the PDTRP motif of the MUC1 tandem repeat only when a specific threonine carries a tumor-type O-glycosylation, allowing discrimination between the aberrantly glycosylated cancer form and normal MUC1. Because it is supplied unconjugated and in bulk milligram-to-gram quantities, it is well suited as a reference binder and assay control, for antibody-dependent cellular cytotoxicity (ADCC) characterization, and as a starting molecule for antibody-drug conjugate (ADC) or bispecific development workflows. It is offered at research-grade low endotoxin (<1 EU/mg), with an ultra-low endotoxin option (<0.5 EU/mg) for sensitive cell-based and preclinical in-vitro standard applications. MUC1 (UniProt P15941; also EMA, CD227, KL-6) is a large type I transmembrane glycoprotein of the mucin family expressed at the apical surface of most glandular and ductal epithelia. It is synthesized as a single chain that is cleaved into two non-covalently associated subunits: a heavily O-glycosylated extracellular alpha subunit dominated by a variable-number tandem repeat (VNTR) region rich in serine and threonine, and a beta subunit comprising a transmembrane domain and a cytoplasmic tail that participates in signaling and protein-protein interactions. In healthy tissue MUC1 provides lubrication, hydration and a protective barrier. In carcinomas it is typically overexpressed, loses apical polarity, and becomes aberrantly (truncated) O-glycosylated, exposing tumor-associated epitopes and contributing to adhesion changes, signaling, invasion and immune modulation, which makes the tumor glycoform an attractive oncology target.

Breast carcinoma-associated antigen DF3, Cancer antigen 15-3, CA 15-3, Carcinoma-associated mucin, Episialin, H23AG, Krebs von den Lungen-6, KL-6, PEMT, Peanut-reactive urinary mucin, PUM, Polymorphic epithelial mucin, PEM, Tumor-associated epithelial mem

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Gatipotuzumab biosimilar available in bulk or gram quantities?

A: Yes — the Gatipotuzumab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Gatipotuzumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Gatipotuzumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Gatipotuzumab that binds MUC1.